Corcept Therapeutics Inc (CORT) 77.49 USD (+0.06%)

Corcept Therapeutics Inc specializes in the development of medications for the treatment of severe endocrine disorders.

medical-research

Price history of Corcept Therapeutics Inc

Performance & Momentum

6 Months 12.48 %

1 Year 4.34 %

3 Years 208.23 %

5 Years 237.30 %

Momentum

Unlock this indicator

Strategic Analysis

Corcept Therapeutics Inc • 2026

Corcept Therapeutics is a biopharmaceutical company specializing in treatments targeting the effects of cortisol, with a highly focused positioning in endocrinology and a potential growth driver in oncology. Its business model is built on niche scientific expertise and monetization tied to clinical development, making it more of a specialty company than a diversified pharmaceutical group.

Strengths

Differentiated therapeutic positioning on the cortisol axis, with rare expertise that is difficult to replicate
Presence in both endocrinology and oncology, providing several potential clinical value drivers
Strong long-term value creation track record, indicating convincing past execution

Weaknesses

High dependence on the success of clinical programs and on the ability to turn research into sustainable revenue
Volatile stock profile, with marked sensitivity to market expectations and narrative revisions

Momentum

Momentum is broadly solid but remains mixed: the underlying trend has been positive over several years, while the recent trend is clearly weaker. For investors, this reflects a speculative quality name, supported by a credible scientific thesis but still exposed to rapid re-rating and correction phases depending on clinical progress.

Analysis performed 1 month ago